Evolution and immediate future of US screening guidelines

Kirsten L. Greene, Sanoj Punnen, Peter R. Carroll

Research output: Contribution to journalReview article

3 Scopus citations

Abstract

Although observational studies and simulation models have shed some interesting light on many of the uncertainties surrounding prostate cancer screening, well-done clinical trials provide the best evidence on screening among the extremes of age, the most appropriate interval to screen, and the best complement of tests to use. Enthusiasm for screening is temporized by the acknowledgment that overdetection leads to frequent overtreatment despite evidence supporting the safety of active surveillance in many men with low-risk disease.

Original languageEnglish (US)
Pages (from-to)229-235
Number of pages7
JournalUrologic Clinics of North America
Volume41
Issue number2
DOIs
StatePublished - May 2014
Externally publishedYes

Keywords

  • Guidelines
  • Prostate cancer
  • Prostate specific antigen (PSA)
  • Public health
  • Screening

ASJC Scopus subject areas

  • Urology

Fingerprint Dive into the research topics of 'Evolution and immediate future of US screening guidelines'. Together they form a unique fingerprint.

  • Cite this